Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

GXM decreases the trans-endothelial electrical resistance (TEER) and transmigration of <i>C</i>. <i>neoformans</i> through HBECs in a blood brain barrier (BBB) model. by Hiu Ham Lee (15374677)

Participant characteristics. by Ronald Kusolo (13200268)

Subjects:

Uganda 2023 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

Subjects:

Uganda 2014 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

Subjects:

Health inequalities in the burden of IBD among WCBA. by Jiefeng Zhao (9090305)

Subjects:

Results of GO analysis showing significantly enriched biological process (BP), cellular component (CC) and molecular function (MF) in genes with significantly decreased expression... by Lucy Granat (5570813)

Study population and coverage for the prevalence survey. by Chandra Kumar Dolla (5278010)

Subjects:

Study population and its coverage. by Chandra Kumar Dolla (5278010)

Subjects:

Risk factors associated with TB. by Chandra Kumar Dolla (5278010)

Subjects:

Estimated prevalence of TB and its associated risk factors. by Chandra Kumar Dolla (5278010)

Subjects:

Significant relationships between QOL measures on infusion day and day 7. by Jordan K. Abbott (8934239)

Subjects:

BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers. by Luqiong Liu (11537092)